The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC

NCT04338399 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

487

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Cancer

Interventions

DRUG: Buparlisib & Paclitaxel

Sponsor

Adlai Nortye Biopharma Co., Ltd.